OUTLOOK THERAPEUTICS INC

Insider buying by Ghiath M. signals confidence in Outlook Therapeutics, a biotech poised to capitalize on its biosimilar platform amid FDA milestones and competitive pressure. Click for analysis.

Insider buying spurs confidence in Outlook Therapeutics as FDA approves eye‑treatment appeal, driving shares 102% higher and raising prospects for a 2026 launch.